Research Grant

[Cite as]

Researchers: Prof Nick Hoogenraad (Principal investigator) ,  Dr Mark Hulett Dr Philip Jennings Prof Andrew Scott Prof John Silke

Brief description Cachexia is a major side effect of cancer, resulting in significant muscle wasting, fat loss and organ failure. Up to 80% of cancer patients suffer and 25% succumb to this condition. This significantly affects the treatment regimens of cancer patients and affects their quality of life. We have developed monoclonal antibodies that block and reverse cachexia in preclinical mouse cancer models. Our aims are to humanise the antibody and manufacture it for the first clinical trial in humans.

Funding Amount $AUD 764,132.83

Funding Scheme Development Grants

Notes Development Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]